Pharosyn raises €2.5m to read pharma's competition for it
The London company, founded last year, sells AI competitive intelligence to drug makers' commercial teams. Moonfire led the round.
Pharosyn has raised €2.5 million. Moonfire led, with Entrepreneurs First, Transpose Platform and General Advance also investing.
The London company was founded in 2025. Its product is a competitive intelligence platform for biopharma.
It monitors clinical, regulatory and commercial data sources, then produces strategic reports matched to a customer's own drug pipeline.
That is the pitch: rather than sell a generic database, the company builds around what a client has in development and what rivals are doing to it.
The company says the infrastructure can be deployed across commercial strategy, portfolio strategy, business development and licensing, market research, forecasting and competitive intelligence. Those are six separate buyers inside a large drug maker, which is a broad target for a company barely a year old.
Pharosyn was founded by Stephen Cowley and Joshua Hampson, who came out of Cambridge University with backgrounds in AI research and biochemistry.
The wider team brings engineering experience in financial forecasting and enterprise productivity, plus senior consulting experience in pharmaceutical commercial strategy at Citeline and at consulting firms.
On the company's account, senior directors at top-10 pharmaceutical companies already use the platform to inform strategic decisions. No customer has been named and no revenue figure has been disclosed.
The money is earmarked for building out the platform and pushing adoption further into commercial and portfolio strategy teams.
Mattias Ljungman, Moonfire's founder, said Pharosyn's founders are "deeply technical, exceptionally tenacious and ambitious" and "rare founders who clearly stand out".
The round lands in a busy year for AI sold into drug development. EU-Startups counts roughly €75.3 million across seven comparable or adjacent European rounds in 2026, including €3.15 million for London-based Sable Bio's drug-safety intelligence, €8.4 million for Helical's virtual AI lab for pharma R&D, €13 million for Rivia's clinical-trial data infrastructure and €43.8 million for Biorce's AI-driven clinical trials.
Set against those, €2.5 million is small. It is also the smallest cheque in that group with the most crowded buyer to reach: pharma commercial teams already pay incumbents such as Citeline for exactly this sort of intelligence.
For founders selling AI into regulated enterprise, the useful detail is the shape of the sale. Pharosyn is not replacing a research subscription; it is embedding inside strategy teams and reporting against their pipeline. That is harder to buy on a corporate card and harder for a rival to rip out once it is in.